The NephJC editorial in Kidney Medicine is live. Great work from Anand Chellapan and Rachael Kermond, supported by Tiffany, Jade and Swap. Read it here.
With a bonus table which already needs updating post EMPAKIDNEY!
This week, we will discuss why a large registry cohort was needed to move past decades of scattered case reports and clarify the true risk of hydralazine‑associated vasculitis. When rare events hide in noise, only scale can reveal the signal. Can population‑level data finally bring this paradox into focus?
Summary of the STEPS trial which will be a twitter spaces discussion
This week, we will discuss the HIT trial- a large randomized study challenging one of the most reflexive responses in hospital medicine: see hyponatremia, fix the sodium. But what if correcting the number doesn’t change what actually matters?
The NephJC editorial in Kidney Medicine is live. Great work from Anand Chellapan and Rachael Kermond, supported by Tiffany, Jade and Swap. Read it here.
With a bonus table which already needs updating post EMPAKIDNEY!
Does the discontinuation of RAS inhibitors improve eGFR in patients with advanced CKD? NSMC Intern Dana Larsen explains it graphically.
If you missed the biggest NephJC of the year, at least read the highlights here.
If you only read one #TenTweetNephJC this year, make it this one.
— Nephrology Journal Club (@NephJC) November 22, 2022
EMPA-KIDNEY is one of those landmark trials it is worth knowing inside-out, but you can still rapidly catch up on the key findings & author tweetchat secrets in the thread below👇 pic.twitter.com/VL2u8BoCLw
Ten Tweet round up of exciting CAR T trial in patients with SLE discussed last month - check it out while you can!
Welcome to #TenTweetNephJC
— Nephrology Jrnl Club (@NephJC) November 18, 2022
✳️ 10 tweets #NephJC catch-up ✳️
Here’s a recap of our 25th Oct #NephJC discussion on ‘Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus’ - better late than never!
Check out the paper at https://t.co/HxTcVC3PtH pic.twitter.com/y7o71HUPiZ
Get the original #KidneyWk Bingo Board here (PDF).
We are not responsible if you get kicked out for yelling “BINGO!”
Basic science week - catch up in only Ten Tweets here.
Welcome to #TenTweetNephJC
— Nephrology Jrnl Club (@NephJC) October 26, 2022
✳️10 tweets #NephJC catch-up ✳️
Perplexed by how gene dosage plays a role in ADPKD? Fascinated by futuristic stories of miRNA,CRISPR & want to see an application closer to daily life?
Read on!Here’s some good news for the ADPKD patient in your clinic. pic.twitter.com/44iFttuRJK
Is Anti-CD19 CAR T Cell therapy an efficacious and tolerable option for refractory SLE?
NSMC intern Susan Thanabalasingam explains it graphically
NSMC intern Sandhya Suresh simplifies the role of mRNA cis-inhibition in PKD progression via a lucid visual abstract